Company news: J&J, Bayer and Siemens Healthcare

Share this article:

Johnson & Johnson/Bayer's Xarelto (rivaroxaban) received FDA approval for stroke prevention in atrial fibrillation (SPAF). It's the second novel anticoagulant to gain US marketing approval in the past 13 months for SPAF, expanding its label from venous thromboembolism (VTE) prophylaxis. It will battle Boehringer Ingelheim's oral anticoagulant Pradaxa for market share in the Afib setting and, if approved, Bristol-Myers Squibb/Pfizer's Eliquis, a SPAF favorite. As expected, Xarelto's label does not include a superior-to-warfarin claim but does emphasize regulators' uncertainty regarding Xarelto's relative merits and has a black-box warning against discontinuing without discussing with a physician.

Siemens Healthcare acquired MobileMD, maker of cloud-based technology which helps hospitals “data enable” physician practices and coordinate care. Terms of the deal, which closed Friday, were not disclosed. MobileMD's health-information exchange tools are in use by more than 110 hospitals and more than 2,000 physician practices. MobileMD helps hospitals connect providers to lab or imaging results and discharge notes and includes online ordering, referrals and scheduling.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.